Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 27, 2023 07:00 ET | Source: Unicycive Therapeutics, Inc.

Unicycive to Highlight Potential of UNI-494 to Restore Mitochondrial Function and Reduce Oxidative Stress at Two Upcoming Medical and Scientific Meetings

Data from two abstracts supporting UNI-494’s potential to treat acute and chronic kidney injury accepted for presentation at the 28th International Conference on Critical Care in Nephrology: the Acute...
February 02, 2023 08:30 ET | Source: Unicycive Therapeutics, Inc.

Unicycive Announces Exclusive License and Development Agreement with Lotus for Renazorb in the Republic of Korea

Develops Renazorb opportunity in new market for patients with hyperphosphatemia Agreement includes upfront payment, royalties, and milestone payments LOS ALTOS, Calif., Feb. 02, 2023 (GLOBE...
January 23, 2023 07:00 ET | Source: Unicycive Therapeutics, Inc.

Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation’s Spring Clinical Meetings

LOS ALTOS, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today...
January 05, 2023 07:00 ET | Source: Unicycive Therapeutics, Inc.

Unicycive Announces Acceptance of Four Abstracts for Presentation at the World Congress of Nephrology 2023

LOS ALTOS, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today...
December 29, 2022 11:31 ET | Source: Unicycive Therapeutics, Inc.

Unicycive Announces Termination of “At-The-Market” Offering of Shares of Common Stock

LOS ALTOS, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today...
December 28, 2022 08:30 ET | Source: Unicycive Therapeutics, Inc.

Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb

Renazorb demonstrates pharmacodynamic bioequivalence to Fosrenol Renazorb’s enhanced product profile features reduced pill burden and small, swallowable tablets, which may improve patient compliance...
December 22, 2022 07:00 ET | Source: Unicycive Therapeutics, Inc.

Unicycive Issued Notice of Acceptance to Initiate Phase 1 Study of UNI-494 Following Review of Clinical Trial Application by the Medicines and Healthcare Products Regulatory Agency in the United Kingdom

LOS ALTOS, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease,...
November 28, 2022 07:00 ET | Source: Unicycive Therapeutics, Inc.

Unicycive to Participate in Upcoming Investor Conferences

LOS ALTOS, Calif., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with unmet medical needs,...
November 21, 2022 07:00 ET | Source: Unicycive Therapeutics, Inc.

Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Geographic Atrophy

Treatment with UNI-494 improved contrast vision in animal models of geographic atrophy (GA) GA is an advanced form of Age-related Macular Degeneration (AMD) and there are currently no FDA-approved...
November 14, 2022 07:00 ET | Source: Unicycive Therapeutics, Inc.

Unicycive Announces Third Quarter Financial Results and Provides Business Update

Topline results by year-end as enrollment completed for pivotal bioequivalence study of RENAZORB™ (lanthanum dioxycarbonate), an investigational phosphate binder for the treatment of hyperphosphatemia...